title: Inhibin alpha-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers.
abstract: The R337H TP53 mutation is a low-penetrance molecular defect that predisposes to adrenocortical tumour (ACT) formation in Brazilian and possibly other populations. Additional genetic defects may be responsible for the variable expression of ACTs in these cases. The inhibin alpha-subunit gene (INHA) on 2q33-qter has been implicated in mouse adrenocortical tumourigenesis. We studied 46 pediatric patients with ACTs from Brazil for INHA genetic alterations; 39 of these patients were heterozygous carriers of the R337H TP53 mutation. We first mapped the INHA gene by radiation hybrid analysis and determined 10 linked microsatellite markers in an area flanked by D2S1371 and D2S206 on 2q33-qter. These markers were then used for loss of heterozygozity (LOH) studies in nine paired germline and tumour DNA samples. Mapping placed the INHA gene in close proximity to D2S2848 (SHGC11864) with a log of odds (LOD) score of 5.84. LOH for at least one marker in the region was identified in 8/9 tumours (89%). Six patients were heterozygous for three INHA mutations: one in exon 1, 127C>G, and two in exon 2, 3998G>A and 4088G>A, all leading to amino acid substitutions (P43A, G227R, and A257T, respectively). A257T is located in a conserved INHA region, highly homologous to transforming growth factor-beta; both G227R and A257T change polarity, and, in addition, G227R changes the pH. We conclude that these sequence alterations and the detected 2q allelic changes suggest that INHA may be one of the contributing factors needed for ACT formation in pediatric patient carriers of the R337H TP53 mutation.
authors.affiliation: Pediatric Endocrinology, Santa Casa de São Paulo, School of Medicine, São Paulo, SP, Brazil.
authors.forename: C A
authors.initials: CA
authors.lastname: Longui
authors.forename: S H V
authors.initials: SH
authors.lastname: Lemos-Marini
authors.forename: B
authors.initials: B
authors.lastname: Figueiredo
authors.forename: B B
authors.initials: BB
authors.lastname: Mendonca
authors.forename: M
authors.initials: M
authors.lastname: Castro
authors.forename: R
authors.initials: R
authors.lastname: Liberatore
authors.forename: C
authors.initials: C
authors.lastname: Watanabe
authors.forename: C L P
authors.initials: CL
authors.lastname: Lancellotti
authors.forename: M N
authors.initials: MN
authors.lastname: Rocha
authors.forename: M B
authors.initials: MB
authors.lastname: Melo
authors.forename: O
authors.initials: O
authors.lastname: Monte
authors.forename: L E P
authors.initials: LE
authors.lastname: Calliari
authors.forename: G
authors.initials: G
authors.lastname: Guerra-Junior
authors.forename: M T M
authors.initials: MT
authors.lastname: Baptista
authors.forename: L
authors.initials: L
authors.lastname: Sbragia-Neto
authors.forename: A C
authors.initials: AC
authors.lastname: Latronico
authors.forename: A
authors.initials: A
authors.lastname: Moreira
authors.forename: A M D
authors.initials: AM
authors.lastname: Tardelli
authors.forename: A
authors.initials: A
authors.lastname: Nigri
authors.forename: S E
authors.initials: SE
authors.lastname: Taymans
authors.forename: C A
authors.initials: CA
authors.lastname: Stratakis
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000235:genetics*; D019943:Amino Acid Substitution; D002648:Child; D002874:Chromosome Mapping; D004252:DNA Mutational Analysis; D016158:Genes, p53; D006579:Heterozygote; D006801:Humans; D007265:Inhibins / Q000235:genetics*; D019656:Loss of Heterozygosity; D009154:Mutation
chemical_list: C094377:inhibin-alpha subunit; D007265:Inhibins